Search Contact
This page is available in multiple languages
Select Language

Svas Biosana S.p.A. lists on Euronext Growth Milan

Back

  • 35th listing of 2021 on Euronext Growth Milan
  • Svas Biosana S.p.A. brings the total number of companies listed on Euronext Growth Milan to 166
  • Total placement volume of the offering equal to €23 million

Milan – 9 December 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Svas Biosana S.p.A. on its listing on Euronext Growth Milan.

Svas Biosana S.p.A. Svas Biosana produces and distributes medical devices in Italy and abroad.

Svas Biosana S.p.A. represents the 35th listing since the beginning of the year on Borsa Italiana’s market dedicated to small and medium sized companies, and it brings the total number of firms currently listed on Euronext Growth Milan to 166.

In the placement phase, Svas Biosana S.p.A. raised €20 million excluding the potential exercise of an over-allotment option. In the case of the full exercise of the over-allotment option, the total amount raised will be €23 million. The free float at the time of admission was 28.57% and the market capitalisation at IPO was €70 million.

Umberto Perillo, CEO of Svas Biosana, said: “We are very proud of the listing on Euronext Growth Milan, and thanks to the listing we will be able to further consolidate our position on the markets. We believe that the geographical expansion of the Group and the strengthening of our production lines will be the pillars of our future path. A special thanks to those who have trusted us, first and foremost the investors, to those who have accompanied us during this exciting journey and to all our employees and collaborators for their valuable professional contribution.”

Svas Biosana Bell Ringing

Caption: Umberto Perillo, CEO of Svas Biosana, rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.

About Svas Biosana S.p.A.

Svas Biosana produces and distributes, in Italy and abroad, medical devices. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, today SVAS is a reality present at international level with a list of 16,000 products under its own and third-party brands, about 367 employees, a department dedicated to Research and Development, three production plants in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia Herzegovina.

Download press release - Svas Biosana S.p.A.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €7.1 trillion in market capitalisation as of end March 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.